Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act
-
Sign-on Letter Concerning Patent Legislation Negotiation Process
-
Group Sign-On Letter for Inlusion of NBSSLRA in Omnibus
-
Group Sign-On Letter for Newborn Screening Appropriations for CY 2022
-
Group Sign-On Letter Concerning the VA Supremacy Project
-
Group Sign-On Letter for Newborn Screening Appropriations for CY 2022
-
Group Sign-On Letter Urging CLIAC to Discuss CLIA Modernization
-
Group Sign-On Letter Supporting the VITAL Act